Catalogue

Choose your language
Phones:
E-mail
hello@peptideseuro.com
We are on social networks
Go to contacts
0 0
Established

Tesamorelin

Modified Growth Hormone-Releasing Hormone Analog

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that has been studied extensively for its effects on visceral adipose tissue and body composition. It is one of the few peptides in this class with published, peer-reviewed clinical data specifically documenting changes in trunk fat. Researchers value it for its selectivity and its well-characterized safety profile.

Aliases: GHRH analog, Egrifta

Research score
10/10
Reality tier
established

Mechanism

Tesamorelin is a synthetic 44-amino acid analog of GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus, providing resistance to dipeptidyl peptidase-4 (DPP-4) degradation. It binds GHRH receptors on anterior pituitary somatotrophs, stimulating GH synthesis and secretion via cAMP signaling. This increases endogenous GH pulsatility while preserving the hypothalamic-pituitary feedback axis. The GH elevation drives IGF-1 production, lipolysis (particularly visceral adipose tissue), and improved body composition.

Evidence note

Established — FDA-approved (Egrifta) with multiple Phase 3 RCTs. Robust human data for visceral fat reduction. Off-label use for anti-aging is well-supported by mechanism but less studied.

Studies

  • Tesamorelin for visceral fat reduction in HIV

    Significantly reduced trunk fat and improved lipid profiles in large-scale RCT.

    Open source · PMID 20592130

  • Tesamorelin and cognitive function

    Improved executive function and verbal memory in adults with mild cognitive impairment or subjective cognitive complaints.

    Open source · PMID 26050793

  • Tesamorelin effects on hepatic fat

    Reduced liver fat and improved markers of NAFLD.

    Open source · PMID 29590385

  • Growth hormone and tesamorelin in the treatment of HIV-associated lipodystrophy

    Tesamorelin significantly reduced visceral adipose tissue in HIV-associated lipodystrophy, providing the basis for FDA approval as Egrifta.

    Open source · PMID 22082200

  • Metabolic effects of a growth hormone-releasing factor in patients with HIV

    Significant trunk fat reduction with improved triglyceride levels in NEJM published trial (Falutz et al.). Key basis study for FDA approval.

    Open source · PMID 17855669

  • Tesamorelin effects on NAFLD and cognitive function in aging

    Emerging data shows NAFLD fat reduction and cognitive improvement in aging populations. Tesamorelin's effects extend beyond HIV lipodystrophy to broader metabolic and neuroprotective applications.

FAQ

How does it compare to Sermorelin?

Both are GHRH analogs. Tesamorelin is more potent, has FDA approval, and has stronger clinical data. Sermorelin has a longer track record and lower cost.

Is Tesamorelin FDA-approved?

Yes. Tesamorelin is FDA-approved as Egrifta® for reduction of excess abdominal fat in HIV-associated lipodystrophy.

Why is it more expensive?

Tesamorelin has higher synthesis costs and is the most potent GHRH analog available with robust Phase III clinical trial data. Its pharmaceutical pedigree commands premium pricing.

How is tesamorelin different from sermorelin?

Both are GHRH analogs, but tesamorelin is a full 44-amino acid GHRH analog with a trans-3-hexenoic acid modification for DPP-4 resistance, while sermorelin is only the first 29 amino acids. Tesamorelin is FDA-approved (Egrifta) with specific clinical data on visceral fat reduction via CT imaging. Sermorelin has broader anti-aging clinic use. Tesamorelin is considered more potent for visceral fat specifically.

Can tesamorelin be stacked with ipamorelin?

Yes — tesamorelin (GHRH pathway) and ipamorelin (ghrelin/GHS pathway) stimulate GH release through two independent receptor systems. This dual-pathway approach is studied for potentially amplified GH output compared to either compound alone. This is one of the most popular GH peptide stacks for targeted visceral fat reduction.

What is the recommended cycle length for tesamorelin?

Published clinical protocols use 2mg SC daily continuously. The research community typically runs 3-6 month cycles with 1-2 month breaks. CT imaging studies showed visceral fat reduction within 8-12 weeks, with continued improvement through 6 months. Most anti-aging practitioners recommend monitoring IGF-1 levels periodically during use.

For research and educational use only. This content is not medical advice.